Health Economics›Cervical cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Cervical cancer · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.8 mo	~15.5 mo	~13	~R 3 730 419 PFS proxy · indirect	40
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~20.4 mo	~51.6 mo	~30	~R 1 717 393 PFS proxy · indirect	3
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	~10.3 mo	—	—	1
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	9.0 mo	—	—	2
Topotecan monotherapy Variant #01	—	R 11 563	21d	—	9.0 mo	—	—	2
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	9.0 mo	—	—	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~3.2 mo	~9.5 mo	~4	~R 973 PFS proxy · indirect	83
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	—	9.0 mo	—	—	2
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	9.0 mo	—	—	2
Cemiplimab monotherapy Variant #01 Partial	—	—	21d	—	11.9 mo	—	—	2
Tisotumab vedotin monotherapy Variant #01 Partial	—	—	21d	—	11.5 mo	—	—	1

12 of 12 regimens shown